Literature DB >> 2168976

Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature.

C Christodoulou1, F Colbere-Garapin, A Macadam, L F Taffs, S Marsden, P Minor, F Horaud.   

Abstract

Poliovirus type 1 neurovirulence is difficult to analyze because of the 56 mutations which differentiate the neurovirulent Mahoney strain from the attenuated Sabin strain. We have isolated four neurovirulent mutants which differ from the temperature-sensitive parental Sabin 1 strain by only a few mutations, using selection for temperature resistance: mutant S(1)37C1 was isolated at 37.5 degrees C, S(1)38C5 was isolated at 38.5 degrees C, and S(1)39C6 and S(1)39C10 were isolated at 39.5 degrees C. All four mutants had a positive reproductive capacity at supraoptimal temperature (Rct+ phenotype). Mutant S(1)37C1 induced paralysis in two of four cynomolgus monkeys, and the three other mutants induced paralysis in four of four monkeys. The lesion score increased from the S(1)37C1 mutant to the S(1)39 mutants. To map the mutations associated with thermoresistance and neurovirulence, we sequenced all regions in which the Sabin 1 genome differs from the Mahoney genome. The S(1)37C1 mutant had one mutation in the 5' noncoding region and another in the 3' noncoding region. Mutant S(1)38C5 had these mutations plus another mutation in the 3D polymerase gene. The S(1)39 mutants had three additional mutations in the capsid protein region. The mutations were located at positions at which the Sabin 1 and Mahoney genomes differ, except for the mutation in the 5' noncoding region. The noncoding-region mutations apparently confer a low degree of neurovirulence. The 3D polymerase mutation, which distinguishes S(1)38C5 and S(1)39 mutants from S(1)37C1, is probably responsible for the high neurovirulence of S(1)38C5 and S(1)39 mutants. The capsid region mutations may contribute to the neurovirulence of the S(1)39 mutants, which was the highest among the mutants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168976      PMCID: PMC247983          DOI: 10.1128/JVI.64.10.4922-4929.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Considerations in the preparation and use of poliomyelitis virus vaccine.

Authors:  J E SALK
Journal:  J Am Med Assoc       Date:  1955-08-06

2.  Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y.

Authors:  N La Monica; V R Racaniello
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  In vitro phenotypic markers of a poliovirus recombinant constructed from infectious cDNA clones of the neurovirulent Mahoney strain and the attenuated Sabin 1 strain.

Authors:  M Kohara; T Omata; A Kameda; B L Semler; H Itoh; E Wimmer; A Nomoto
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.

Authors:  R Crainic; B Blondel; A Candréa; G Dufraisse; F Horaud
Journal:  Dev Biol Stand       Date:  1985

5.  A poliovirus temperature-sensitive RNA synthesis mutant located in a noncoding region of the genome.

Authors:  P Sarnow; H D Bernstein; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

6.  Genetic analysis of the attenuation phenotype of poliovirus type 1.

Authors:  T Omata; M Kohara; S Kuge; T Komatsu; S Abe; B L Semler; A Kameda; H Itoh; M Arita; E Wimmer
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

Authors:  H Toyoda; M Kohara; Y Kataoka; T Suganuma; T Omata; N Imura; A Nomoto
Journal:  J Mol Biol       Date:  1984-04-25       Impact factor: 5.469

9.  Poliovirus-specific polypeptides in infected HeLa cells analysed by isoelectric focusing and 2D-analysis.

Authors:  K J Wiegers; R Dernick
Journal:  J Gen Virol       Date:  1981-01       Impact factor: 3.891

10.  Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice.

Authors:  A Martin; C Wychowski; T Couderc; R Crainic; J Hogle; M Girard
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

View more
  40 in total

1.  Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture.

Authors:  K Matsuura; M Ishikura; H Yoshida; T Nakayama; S Hasegawa; S Ando; H Horie; T Miyamura; T Kitamura
Journal:  Appl Environ Microbiol       Date:  2000-11       Impact factor: 4.792

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells.

Authors:  Stephanie A Campbell; Jennifer Lin; Elena Y Dobrikova; Matthias Gromeier
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain.

Authors:  A J Macadam; G Ferguson; C Arnold; P D Minor
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

9.  Cumulative mutations in the genome of Echovirus 6 during establishment of a chronic infection in precursors of glial cells.

Authors:  Frederik Beaulieux; Youssef Zreik; Christelle Deleage; Valerie Sauvinet; Vincent Legay; Pascale Giraudon; Katherine M Kean; Bruno Lina
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

10.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.